Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Tvardi Therapeutics, Inc.
Bear Case (25th pct.)
17.2% vs price
Base Case (Median)
43.4% vs price
Bull Case (75th pct.)
111.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $2.77 | 179.6% | High (40%) |
| PE Comparable | $0.91 | -8.0% | Medium (25%) |
| Graham Number | $1.42 | 43.2% | Medium (40%) |
Based on 3 out of 7 methods, TVRD appears undervalued at the current price of $0.99. The base case fair value of $1.42 implies 43.4% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.